[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] CHEN P X, LIU Y H, WEN Y K, et al. Non-small cell lung cancer in China[J]. Cancer Commun, 2022, 42(10): 937-970. doi:  10.1002/cac2.12359
[3] ETTINGER D S, WOOD D E, AISNER D L, et al. NCCN guidelines® insights: non-small cell lung cancer, version 2.2023[J]. J Natl Compr Canc Netw, 2023, 21(4): 340-350. doi:  10.6004/jnccn.2023.0020
[4] OWEN D H, ISMAILA N, AHLUWALIA A, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.3[J]. J Clin Oncol, 2025, 43(10): e2-e16.
[5] LI R J, LI W Y, ZHANG F, et al. Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials[J]. Eur J Med Res, 2023, 28(1): 302. doi:  10.1186/s40001-023-01272-7
[6] MOSCA M, CONCI N, DI FEDERICO A, et al. First-generation epidermal growth factor receptor inhibitors plus antiangiogenic drugs versus third-generation epidermal growth factor receptor inhibitors in advanced non-small-cell lung cancer: a meta-analysis[J]. JCO Precis Oncol, 2023, 7: e2300073.
[7] HIGGINS J P T, ALTMAN D G, GØTZSCHE P C, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343: d5928. doi:  10.1136/bmj.d5928
[8] CHAIMANI A, HIGGINS J P T, MAVRIDIS D, et al. Graphical tools for network meta-analysis in STATA[J]. PLoS One, 2013, 8(10): e76654. doi:  10.1371/journal.pone.0076654
[9] SHIM S R, KIM S J, LEE J, et al. Network meta-analysis: application and practice using R software[J]. Epidemiol Health, 2019, 41: e2019013. doi:  10.4178/epih.e2019013
[10] IOANNIDIS J P A. Interpretation of tests of heterogeneity and bias in meta-analysis[J]. J Eval Clin Pract, 2008, 14(5): 951-957. doi:  10.1111/j.1365-2753.2008.00986.x
[11] MBUAGBAW L, ROCHWERG B, JAESCHKE R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses[J]. Syst Rev, 2017, 6(1): 79. doi:  10.1186/s13643-017-0473-z
[12] SALANTI G, ADES A E, IOANNIDIS J P A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial[J]. J Clin Epidemiol, 2011, 64(2): 163-171. doi:  10.1016/j.jclinepi.2010.03.016
[13] STERNE J A C, SUTTON A J, IOANNIDIS J P A, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials[J]. BMJ, 2011, 343: d4002. doi:  10.1136/bmj.d4002
[14] MITSUDOMI T, MORITA S, YATABE Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial[J]. 2010, 11(2): 121-128.
[15] YOSHIOKA H, SHIMOKAWA M, SETO T, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer[J]. Ann Oncol, 2019, 30(12): 1978-1984. doi:  10.1093/annonc/mdz399
[16] INOUE A, KOBAYASHI K, MAEMONDO M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations(NEJ002)[J]. Ann Oncol, 2013, 24(1): 54-59. doi:  10.1093/annonc/mds214
[17] MAEMONDO M, INOUE A, KOBAYASHI K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR[J]. N Engl J Med, 2010, 362(25): 2380-2388. doi:  10.1056/NEJMoa0909530
[18] ZHOU C C, WU Y L, CHEN G Y, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. 2011, 12(8): 735-742.
[19] ZHOU C, WU Y L, CHEN G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer(OPTIMAL, CTONG-0802)[J]. Ann Oncol, 2015, 26(9): 1877-1883. doi:  10.1093/annonc/mdv276
[20] ROSELL R, CARCERENY E, GERVAIS R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. 2012, 13(3): 239-246.
[21] YANG J C, WU Y L, SCHULER M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma(LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials[J]. 2015, 16(2): 141-151.
[22] SEQUIST L V, YANG J C, YAMAMOTO N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. J Clin Oncol, 2023, 41(16): 2869-2876. doi:  10.1200/JCO.22.02547
[23] WU Y L, ZHOU C C, HU C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. 2014, 15(2): 213-222.
[24] WU Y L, ZHOU C, LIAM C K, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study[J]. Ann Oncol, 2015, 26(9): 1883-1889. doi:  10.1093/annonc/mdv270
[25] SHI Y K, WANG L, HAN B H, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J]. Ann Oncol, 2017, 28(10): 2443-2450. doi:  10.1093/annonc/mdx359
[26] PARK K, TAN E H, O’BYRNE K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. 2016, 17(5): 577-589.
[27] PAZ-ARES L, TAN E H, O’BYRNE K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial[J]. Ann Oncol, 2017, 28(2): 270-277. doi:  10.1093/annonc/mdw611
[28] YANG J J, ZHOU Q, YAN H H, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations[J]. Br J Cancer, 2017, 116(5): 568-574. doi:  10.1038/bjc.2016.456
[29] MOK T S, CHENG Y, ZHOU X D, et al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J]. Drugs, 2021, 81(2): 257-266. doi:  10.1007/s40265-020-01441-6
[30] WU Y L, CHENG Y, ZHOU X D, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050): a randomised, open-label, phase 3 trial[J]. 2017, 18(11): 1454-1466.
[31] MOK T S, CHENG Y, ZHOU X D, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J]. J Clin Oncol, 2018, 36(22): 2244-2250. doi:  10.1200/JCO.2018.78.7994
[32] RAMALINGAM S S, VANSTEENKISTE J, PLANCHARD D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC[J]. 2020, 382(1): 41-50.
[33] SORIA J C, OHE Y, VANSTEENKISTE J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. 2018, 378(2): 113-125.
[34] LU S, DONG X R, JIAN H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol, 2022, 40(27): 3162-3171. doi:  10.1200/JCO.21.02641
[35] SHI Y K, CHEN G Y, WANG X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study[J]. 2022, 10(11): 1019-1028.
[36] CHENG Y, MURAKAMI H, YANG P C, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations[J]. J Clin Oncol, 2016, 34(27): 3258-3266. doi:  10.1200/JCO.2016.66.9218
[37] YANG J C, CHENG Y, MURAKAMI H, et al. A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival and biomarker analysis[J]. J Thorac Oncol, 2020, 15(1): 91-100. doi:  10.1016/j.jtho.2019.09.008
[38] LOU Y Q, XU J L, ZHANG Y W, et al. Chemotherapy plus EGFR-TKI as first-line treatment provides better survival for advanced EGFR-positive lung adenocarcinoma patients: updated data and exploratory in vitro study[J]. Target Oncol, 2020, 15(2): 175-184. doi:  10.1007/s11523-020-00708-y
[39] HAN B H, JIN B, CHU T Q, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial[J]. Int J Cancer, 2017, 141(6): 1249-1256. doi:  10.1002/ijc.30806
[40] XU L S, QI Q, ZHANG Y, et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: a randomized controlled study[J]. Lung Cancer, 2019, 133: 23-31. doi:  10.1016/j.lungcan.2019.05.008
[41] NORONHA V, PATIL V M, JOSHI A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer[J]. J Clin Oncol, 2020, 38(2): 124-136. doi:  10.1200/JCO.19.01154
[42] HOSOMI Y, MORITA S, SUGAWARA S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study[J]. J Clin Oncol, 2020, 38(2): 115-123. doi:  10.1200/JCO.19.01488
[43] MIYAUCHI E, MORITA S, NAKAMURA A, et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. J Clin Oncol, 2022, 40(31): 3587-3592. doi:  10.1200/JCO.21.02911
[44] SETO T, KATO T, NISHIO M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study[J]. 2014, 15(11): 1236-1244.
[45] SAITO H, FUKUHARA T, FURUYA N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer(NEJ026):interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. 2019, 20(5): 625-635.
[46] STINCHCOMBE T E, JÄNNE P A, WANG X F, et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(10): 1448-1455. doi:  10.1001/jamaoncol.2019.1847
[47] NAKAGAWA K, GARON E B, SETO T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. 2019, 20(12): 1655-1669.
[48] ZHAO H Y, YAO W X, MIN X H, et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706)[J]. J Thorac Oncol, 2021, 16(9): 1533-1546. doi:  10.1016/j.jtho.2021.05.006
[49] ZHOU Q, XU C R, CHENG Y, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study[J]. Cancer Cell, 2021, 39(9): 1279-1291. e3.
[50] KENMOTSU H, WAKUDA K, MORI K, et al. Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study[J]. J Thorac Oncol, 2022, 17(9): 1098-1108. doi:  10.1016/j.jtho.2022.05.006
[51] PICCIRILLO M C, BONANNO L, GARASSINO M C, et al. Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial[J]. J Thorac Oncol, 2022, 17(9): 1086-1097. doi:  10.1016/j.jtho.2022.05.008
[52] GOLDBERG S B, REDMAN M W, LILENBAUM R, et al. Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer: final results from SWOG S1403[J]. J Clin Oncol, 2020, 38(34): 4076-4085. doi:  10.1200/JCO.20.01149
[53] YAO X Y, GAO C D, SUN C G, et al. Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: Elucidation of mechanisms and perspectives on therapeutic strategies[J]. Drug Discov Today, 2025, 30(3): 104321. doi:  10.1016/j.drudis.2025.104321
[54] HE J Y, HUANG Z R, HAN L Z, et al. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)[J]. Int J Oncol, 2021, 59(5): 90. doi:  10.3892/ijo.2021.5270
[55] ZHAO Y, LIU J T, CAI X Y, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis[J]. BMJ, 2019, 367: l5460.
[56] YANG F, ZHANG W G, SHANG X L, et al. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: a systematic review and network meta-analysis[J]. Crit Rev Oncol Hematol, 2022, 177: 103760. doi:  10.1016/j.critrevonc.2022.103760